Progress in the Typhoid Conjugate Vaccine Program Rollout Supported by Gavi During the COVID-19 Pandemic and the Path Forward
Allyson R. Nelson, Lee M. Hampton, Antara Sinha, Francisco J. Luquero, J. Abdelwahab
Abstract
Gavi supports countries to introduce typhoid conjugate vaccine (TCV) with catch-up campaigns. Available TCVs are highly efficacious, equity-focused, and critical to curbing the expansion of antimicrobial resistance. Four Gavi-supported countries have introduced TCVs since 2018. In the wake of the COVID-19 emergency, momentum is building to scale up TCV introduction worldwide, supported by global partners and Gavi's funding for improved typhoid diagnostics.
Topics & Concepts
PandemicMedicineCoronavirus disease 2019 (COVID-19)Typhoid feverVirology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ConjugateOutbreakInternal medicineDiseaseMathematicsInfectious disease (medical specialty)Mathematical analysisSalmonella and Campylobacter epidemiologyViral gastroenteritis research and epidemiologyVibrio bacteria research studies